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The dynamic evolution of chromatin state patterns duringmetastasis, their relationshipwith bona fide genetic
drivers, and their therapeutic vulnerabilities are not completely understood. Combinatorial chromatin state
profiling of 46 melanoma samples reveals an association of NRAS mutants with bivalent histone H3 lysine
27 trimethylation (H3K27me3) and Polycomb repressive complex 2. Reprogramming of bivalent domains dur-
ing metastasis occurs on master transcription factors of a mesenchymal phenotype, including ZEB1,
TWIST1, and CDH1. Resolution of bivalency using pharmacological inhibition of EZH2 decreases invasive
capacity of melanoma cells and markedly reduces tumor burden in vivo, specifically in NRASmutants. Coin-
cident with bivalent reprogramming, the increased expression of pro-metastatic and melanocyte-specific
cell-identity genes is associated with exceptionally wide H3K4me3 domains, suggesting a role for this epige-
netic element. Overall, we demonstrate that reprogramming of bivalent and broad domains represents key
epigenetic alterations in metastatic melanoma and that EZH2 plus MEK inhibition may provide a promising
therapeutic strategy for NRAS mutant melanoma patients.
INTRODUCTION
Melanoma is a deadly disease with an estimated 100,000 new
cases each year in the United States (Lens and Dawes, 2004;
Miller and Mihm, 2006). While targeted therapy and immuno-
therapy have become the standard of care with significant
improvement in clinical response, thousands of patients still suc-
cumb to this disease per year due to primary or acquired resis-
tance (Rosenberg et al., 2011; Tawbi et al., 2018).
Large-scale efforts from consortiums such as The Cancer
Genome Atlas (TCGA) have provided deeper understanding of
molecular aberrations in metastatic melanoma (Cancer Genome
Atlas Network, 2015; Hodis et al., 2012; Tsao et al., 2012). These
studies identified critical somatic mutations in this disease that
likely occur due to UV exposure. Among these, somatic muta-
tions in important bona fide oncogenes and tumor suppressors,
such as BRAF,NRAS, NF1, INK/ARF, PTEN, and TP53, are well-
chronicled drivers of this malignancy (Cancer Genome Atlas
Network, 2015; Hodis et al., 2012; Tsao et al., 2012). One of
the important findings from these studies was genetic aberra-
tions in several key epigenetic regulators such as EZH2, IDH1/
2, ARID2, KMT2C, and KMT2D (Cancer Genome Atlas Network,
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2015; Hodis et al., 2012; Tsao et al., 2012), many of which are en-
zymes that control the covalent modifications of histones (Cec-
carelli et al., 2016; Hodis et al., 2012; Ortega-Molina et al.,
2015; Simon and Lange, 2008; Vallianatos and Iwase, 2015;
Wu and Roberts, 2013). Although recent studies provide insight
into the correlation of isolated chromatin modifiers and histone
marks, there are a myriad of possible combinatorial patterns of
histone modifications, and it is these combinatorial states—not
individual modifications—that dictate epigenetic status of asso-
ciated genomic loci (Lin et al., 2016; Lomberk et al., 2018; Roe
et al., 2017). These observations suggest that epigenetic alter-
ations, including those in histone modifications, may play impor-
tant roles in melanoma progression. Indeed, specific functional
roles have been assigned to histone variants such as macroH2A
and H2A.z in melanoma (Kapoor et al., 2010; Vardabasso et al.,
2015).
Taken together, these studies provide a strong rationale for
systematic mapping of the epigenome to obtain a comprehen-
sive understanding of regulatory elements that may act as driver
events in particular melanoma tumors. This concept has been
epitomized by DNA methylation studies in a large number of tu-
mors profiled by TCGA. For example, a hypermethylation pheno-
type, termed CpG island methylation phenotype (CIMP), is a
common epigenetic feature in various cancer types and tightly
associated with critical driver gene mutations (i.e., IDH1) (Cec-
carelli et al., 2016; Noushmehr et al., 2010; Weisenberger,
2014). Furthermore, other projects, such as ENCODE and Road-
map Epigenomics, have cataloged extensive histone modifica-
tion in normal human tissues and cell lines. These studies pro-
vide critical information regarding tissue-specific regulatory
elements, the link between relevant cell types and distinct human
traits, and insight for evaluating the epigenetic basis of human
diseases (ENCODE Project Consortium, 2012; Kundaje et al.,
2015). Importantly, chromatin state mapping in a large number
of tumors and cancer cell lines has the potential to enhance
these concepts by identifying these regulatory features directly
in a disease model (Corces et al., 2018). Since epigenetic aber-
rations are reversible by targeting their enzyme regulators, chro-
matin profiling can further identify therapeutic strategies in
specific genetic or phenotypic contexts. For example, our previ-
ous study suggested histone deacetylase (HDAC) inhibitors
could be a good strategy to block the initiation of pre-malignant
to malignant melanoma in cell line systems (Fiziev et al., 2017).
During normal development histone modifications work in
concert with other chromatin modifiers and transcription factors
(TFs) to control the spatial and temporal regulation of gene
expression patterns (Dambacher et al., 2010; Sarmento et al.,
2004). In this context, the identity of each cell type, and its asso-
ciated gene expression pattern, is maintained and subsequently
inherited by daughter cells throughmechanisms that do not alter
the DNA sequence (Dambacher et al., 2010; Sarmento et al.,
2004). Bivalent chromatin domains are characterized by the con-
current enrichment of active (i.e., Histone H3 lysine 4 trimethyla-
tion [H3K4me3]) and repressive (i.e., H3K27me3) histone modifi-
cations (Bernstein et al., 2006). During organogenesis, switches
in bivalent domains can rapidly control the expression of critical
lineage-specific genes that gain or lose these modifications as
cells differentiate toward a particular phenotype (Bernstein
et al., 2006; Voigt et al., 2013). In normal cells, bivalent marks
are found at cancer-related genes (i.e., CDKN2A) with roles spe-
cific to the development of those tissues (Jadhav et al., 2016).
Hence, it is plausible these genes were active during organogen-
esis, and an aberrant TF or epigenetic modification can leave
them vulnerable to transcription in adult cells. Indeed, these
studies have suggested tissue-specific mechanisms recruit his-
tone methyltransferase Polycomb repressive complex 2 (PRC2)
to place H3K27me3 at gene promoters in order to avoid un-
wanted mRNA expression (Jadhav et al., 2016). In melanoma tu-
mors, H3K27me3 and Enhancer of zeste homolog 2 (EZH2) are
predominantly expressed at the invasion front and have been
linked to an invasive, epithelial-mesenchymal transition (EMT)-
associated phenotype (Hoffmann et al., 2020). However, the
role of bivalent H3K27me3 chromatin states and the involvement
of PRC2 in metastatic melanoma have yet to be described.
In this study, we present a comprehensive chromatin state
analysis of metastatic melanoma by performing chromatin
immunoprecipitation sequencing (ChIP-seq) of 6 core histone
modification marks using 46 melanoma tumors and cell lines.
By integrative analysis of various omic datasets, we identify biva-
lent H3K27me3 and exceptionally wide H3K4me3 domains as
potential drivers of amesenchymal phenotype inmetastatic mel-
anoma, primarily in the NRAS mutant population. Mechanisti-
cally, the misappropriation of bivalent chromatin domains and
increased levels of polycomb protein SUZ12 in NRAS mutant
melanomas provide a plausible mechanism for the deregulation
of pro-mesenchymal gene expression. Therapeutically, we
demonstrate that the combination of EZH2 plus Mitogen-acti-
vated protein kinase kinase (MEK) inhibitors markedly reduces
tumor burden in NRAS mutant cells, but not BRAF mutant cells.
Thus, we provide evidence for genotype-dependent epigenome
reprogramming in melanomas and show that disruption of PRC2
in combination with MEK inhibition may provide a promising
therapeutic strategy for NRAS melanoma patients.
RESULTS
Bivalent H3K27me3 chromatin domains are enriched in
metastatic melanoma
Chromatin state profiling remains a powerful tool for determining
the regulatory status of annotated genes and identifying de novo
elements in non-coding genomic regions (Kundaje et al., 2015).
We identified enhancers (H3K27ac and H3K4me1), promoters
(H3K4me3), actively transcribed loci (H3K79me2), polycomb
silenced loci (H3K27me3), and heterochromatin (H3K9me3)
elements in 46 melanoma samples by ChIP-seq using a high-
throughput ChIP-seq protocol adapted for tumor tissues (Terra-
nova et al., 2018). These constituted 20 metastatic melanoma
tumors (TCGA [Cancer Genome Atlas Network, 2015]), 10 pa-
tient-derived melanoma short-term cultures (MSTCs; passage
n < 10; profiled by internal effort at MD Anderson; unpublished
data), and 16 established melanoma lines profiled by the Cancer
Cell Line Encyclopedia/Sanger (CCLE) (Barretina et al., 2012)
(Table S1). Using our cohort of 20 metastatic melanoma tumor
samples, we computed multiple chromatin state models (2-state
through30-statemodels)with theChromHMMalgorithm (Figures
1A and S1A). We annotated an 18-state model since it is
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large enough to identify non-redundant functional elements en-
compassing canonical chromatin states that were not captured
using lower state models (Figure S1A). These included such
states as active promoters (E1); genic (E5, E6) and active en-
hancers (E7, E8) harboring high levels of H3K27ac and
H3K4me1; and heterochromatic (E10) or polycomb (E14)-based
repression harboring high levels of either H3K9me3 or
H3K27me3, respectively (Figures 1AandS1B).Wealso observed
two prominent bivalent/poised states: first, harboring both
H3K4me3 and high levels of H3K9me3 (E12, annotated as
‘‘poised H3K9me3’’); and second, H3K4me3 and high levels of
H3K27me3 (E13, annotated as ‘‘poised H3K27me3’’). Overall,
the chromatin state profiles in metastatic melanoma tumors are
associated with gene expression patterns (Figure 1B). As ex-
pected, active chromatin states (E1–E8) are associated with
high gene expression levels, whereas repressed states (E10
and E15) are associated with low gene expression levels
(Figure 1B).
This TCGA tumor cohort is inclusive of well-described mela-
noma subgroups (Cancer Genome Atlas Network, 2015),
including mutation (BRAF, NRAS, WT), transcriptomic (immune,
keratin, Melanocyte inducing transcription factor [MITF]-low),
and DNA methylation (CpG, hypermethlyated, hypomethylated,
normal) subtypes (Figures S2A and S2B; Table S1). Projection
of chromatin state data using multidimensional scaling (MDS)
analysis revealed chromatin state E13 (poised H3K27me3) sepa-
rated NRASmutant tumors from BRAF mutant and WT samples
in the first dimension (Figures 1C, 1D, and S2C). Moreover, dif-
ferential analysis of bivalent chromatin states demonstrated
NRAS enrichment for poised H3K27me3 domains (Figures 1E,
S2D, and S2E). The identification of all potential bivalent combi-
nations revealed a marked increase of bivalent H3K27me3, but
not H3K9me3 or H3K27/H3K9me3, in tumor samples, MSTCs,
CCLE lines, and isogenic mutant melanocytes harboring an
NRASQ61K or BRAFV600E mutation (Fiziev et al., 2017; Garraway
et al., 2005; Rai et al., 2015) (Figures 1F–1K and S3A–S3E). In
accordance with our chromatin state analysis, NRAS mutants
displayed the greatest number of bivalent H3K27me3 loci out
of all the subgroups, whereas WT samples displayed the least
number of bivalent loci on a global and meta-gene level (Figures
1F, 1G, and S3A–S3E). Similarly, NRASQ61K isogenic mutants
(pNRAS) contained increased bivalent H3K27me3-associated
loci compared with BRAFV600E mutants (pBRAF) (Figures 1H
and 1I). Overlaps of bivalent domains in metastatic (m) mNRAS
and mBRAF mutant tumors to those of isogenic mutants, as
well as k-means clustering of H3K4me3 and H3K27me3 across
all samples, showed enrichment of bivalent chromatin on both
a genome-wide andmeta-gene level (Figures 1J and 1K). Finally,
we noted substantial overlaps between MSTC bivalent loci with
the metastatic mNRAS and mBRAF mutant groups (Figures S3F
and S3G), further demonstrating bivalent chromatin domains are
enriched in NRAS mutant metastatic melanoma.
Bivalent domains are lost and gained on key
mesenchymal genes
Previous studies have demonstrated various cancer-related
genes (i.e., CDKN2A) maintain or acquire bivalent promoters in
normal tissues (Jadhav et al., 2016); however, their role in mela-
noma progression has yet to be described. To determine how
subtype-specific bivalent H3K27me3 losses and gains influence
in melanoma progression, we calculated the overlaps of bivalent
sites from mNRAS and mBRAF mutants to those in isogenic
mutant melanocytes (pNRAS and pBRAF) and primary melano-
cytes (unmodified) from Roadmap data (Figures 2A and S3H–
S3K). We observed a potential shift in bivalent domains as
melanocytes progress towardmelanoma, with a global decrease
of bivalent loci in BRAF mutants and a global increase in NRAS
mutants (Figures 2B and 2C). Average density analysis of these
bivalent domains displayed low levels of active transcription
marks (H3K27ac and H3K79me2) within these regions, further
suggesting these domains are truly bivalent (Figures 2D–2F).
We posited that removal of H3K27me3 mark from bivalent loci
in melanocytes (‘‘bivalent losses’’) would lead to transcriptionally
‘‘active’’ loci in melanoma tumors, whereas gains of H3K27me3
mark on loci (‘‘bivalent gains’’) that harbor H3K4me3 in melano-
cytes (bivalent in tumors) will lead to transcriptional repression
(Figure S3L). Determination of the gene targets (within 10 kilo-
bases [kb] of TSSs to transcription end sites [TESs]) and subse-
quent pathway enrichment of bivalent gains and losses identified
critical melanoma-associated ‘‘hallmark pathways’’ within each
Figure 1. Bivalent H3K27me3 chromatin states are enriched in metastatic melanoma
(A) Combinatorial chromatin state definitions and histone mark probabilities identified in 20 metastatic melanoma tumor samples using the ChromHMM algo-
rithm.
(B) Boxplot illustrating mean gene expression levels from RNA-seq based on genomic regions overlapping with each chromatin state.
(C and D) MDS analysis of chromatin state E13 (poised H3K27me3 high) annotated by mutation (NRAS, BRAF, WT). (D) RNA expression (immune, keratin, MITF-
low) and DNA methylation (normal, CpG, hyper, hypo) classifications from The Cancer Genome Atlas.
(E) Heatmap displaying differentially regulated regions (false discovery rate [FDR] < 0.05) of chromatin state E13 (poised H3K27me3 high) between NRAS and
BRAF tumor subtypes. p values were calculated using a Wilcoxon test.
(F) Common bivalent H3K27me3 (H3K4me3 + H3K27me3), bivalent H3K9me3 (H3K4me3 + H3K9me3) and bivalent H3K27/H3K9me3 (H3K4me3 + H3K27me3 +
H3K9me3) loci in melanoma tumor subtypes and melanoma short-term cultures (MSTCs) and CCLE lines.
(G) Co-occupancy analysis of common bivalent associated loci in melanoma tumor subtypes directly overlapping bivalent loci in representative MSTCs or CCLE
lines.
(H) Barplot of H3K4me3 and H3K27me3 associated loci in isogenic mutant melanocytes harboring an NRAS (pNRAS) or BRAF (pBRAF) mutation.
(I) Venn diagram analysis of bivalent loci in pNRAS and pBRAF isogenic mutant melanocytes.
(J) Venn diagram analysis of bivalent loci inNRAS and BRAFmutant melanoma tumors with isogenic mutant melanocytes harboring anNRAS or BRAFmutation.
(K) Heatmap of H3K4me3 and H3K27me3 signal at10 to +10 kb around transcription start sites (TSSs) of all ensemble genes inNRASmutant melanoma tumors
(mNRAS), BRAF mutant melanoma tumors (mBRAF), WT melanoma tumors (mWT), MSTCs, CCLE cell lines, and isogenic mutant melanocytes harboring an
NRAS or BRAF mutation.
See also Figures S1–S3 and Table S1.











Figure 2. Bivalent domains are lost and gained on mesenchymal genes
(A) Venn diagram analysis of bivalent H3K27me3 loci in mNRAS, mBRAF, and mWT tumor subtypes.
(B andC) Venn diagram analysis of unique bivalent H3K27me3 loci inmNRAS. (C)mBRAF tumor subtypes overlapping bivalent polycomb sites in isogenicmutant
melanocytes and primary melanocytes from Roadmap.
(D–F) Average density profiles of H3K4me3, H3K27me3, H3K27ac, and H3K79me3 in mNRAS and mBRAF melanoma tumor subtypes. (E) Isogenic mutant
melanocytes and (F) primary melanocytes from Roadmap.
(legend continued on next page)




genetic subgroup (Figure 2G). For example, in NRAS mutants,
losses of melanocyte-specific bivalency included genes associ-
ated with the ‘‘EMT’’ and ‘‘KRAS-signaling up,’’ while gains of
tumor-specific bivalency included genes associated with
‘‘KRAS-signaling down’’ and ‘‘apical junction’’ (Figure 2G; Table
S2). Apart from known activation of RAS-RAF pathway genes,
various studies have demonstrated importance of mesenchymal
driver genes in the invasive behavior of metastatic melanoma
and other malignancies (Brabletz et al., 2018; Caramel et al.,
2013; Kalluri and Weinberg, 2009).
Identification of metastatic drivers that are subjected to bivalent
regulation included key EMT-TFs ZEB1, TWIST1, SNAI1, and
CDH1, which do not harbor genetic changes in melanoma (Fig-
ure S3M). On the TWIST1 and ZEB1 promoters, we foundmelano-
cytes harbor a bivalent configuration similar to that of embryonic
stem cells (ESCs), which further switches to a transcriptionally
active state upon isogenic mutation and remains active during
metastasis (Figures 2H, 2I, S3N, S3O, S4A, and S4B). Genes
such asSNAI1, however, continue to retain a bivalent configuration
upon isogenicmutation and are transcriptionally active only inmet-
astatic samples (Figures S3N and S3O). In contrast to bivalent
losses, ongenessuchasCDH1andCDH3we foundESCsandme-
lanocytes harbor transcriptionally active H3K4me3 and gain
repressive bivalency upon isogenic mutation (Figures 2J, 2K,
S4A, and S4B), suggesting EMT-TFs are dynamically regulated
duringmelanomaprogression. Importantly, thesebivalent switches
are significantly correlated with mRNA expression levels in our pri-
mary cohort or in a large cohort of metastatic tumors from TCGA.
Since bivalent domains in ESCs are known to be functional, allow-
ing either rapid transcriptional activation or progression to stable
silencing of gene expression, it is plausible thesemelanocyte-spe-
cific bivalent domains are functionally poised for activation.
A subset of melanocyte-specific bivalent genes
transition to transcriptionally active broad H3K4me3
In contrast to typical H3K4me3 domains that are usually 200–
1,000 bp long, broad H3K4me3 domains can span thousands
of kilobases and have been implicated in various cellular pro-
cesses, including increased gene expression, enhancer activity,
and tumor-suppressor gene regulation (Benayoun et al., 2014;
Chen et al., 2015; Dahl et al., 2016). Hence, we posited that
genes losing bivalency in melanocytes may retain or acquire
different signatures (broad or non-broad) of H3K4me3 in mela-
noma tumors. To this end, we systematically identified broad
H3K4me3 domains by computing the overall width and density
fromMACS2 broad peaks in melanoma tumors and primary me-
lanocytes (Figures 3A–3D). Globally, mNRAS and mBRAF
mutant subtypes, as well as primary melanocytes, harbored
the largest number of broad H3K4me3 peaks, in some cases
spanning >30 kb (Figure 3A).We observed the broadest domains
extended well beyond that of typical H3K4me3 (200–1,000 bp),
with peaks reaching >4 kb in 15 of 17 of the individual samples
(mNRAS and mBRAF) (Figures S4C and S4D). Separation of do-
mains >4 kb to domains <4 kb revealed two distinct types of
H3K4me3 in melanoma tumors, including broad domains span-
ning outside of the transcription start site (TSS) and non-broad
domains localized within the promoter region (Figures 3E and
S4E). Consistent with previous studies (Chen et al., 2015), we
observed other epigenetic marks coincide with H3K4me3
domain width, in which active H3K27ac, H3K4me1, and
H3K79me2 had similarly wide peaks at promoters harboring
broad H3K4me3 (Figure 3E).
To identify the subsets of melanocyte-specific bivalent genes
that transition to transcriptionally active broad domains (and
lose H3K27me3 in tumors), we further overlapped genes that har-
bor (1) bivalent domains uniquely in melanocytes (but not in tu-
mors), (2) tumor-specific broad or non-broad H3K4me3 domains,
(3) active transcription mark H3K79me2, and (4) gene expression
(using TCGA RNA-seq data [Cancer Genome Atlas Network,
2015; Colaprico et al., 2016] from mNRAS [n = 81], mBRAF [n =
118], and mWT [n = 38] metastatic samples). Integrative analysis
revealed mNRAS-specific broad domains were associated with
increased gene expression (Figures 3F–3I; Table S3) and enriched
for melanoma pathways such as ‘‘KRAS signaling up,’’ ‘‘UV
response up,’’ and ‘‘Glycolysis’’ (Figure 3J). Genes displaying
the transition to transcriptionally active broad H3K4me3 included
critical metastatic drivers known to function in the switch to a
mesenchymal/invasive state, including SOX9, PDGFA, PDGFRA,
and MYCN (3.7 kb width) (Figures 3K, 3L, S4F, and S4G), sug-
gesting a role for broad H3K4me3 domains in the regulation of
mesenchymal genes in melanoma. In contrast to broad domains,
we identified a relatively large and constant number of genes tran-
sitioning from a bivalent state to non-broad H3K4me3, many of
which were shared in NRAS and BRAF mutants and associated
with increased expression levels (Figures 3F–3I).
Broad H3K4me3 domain shortening correlates with
transcriptional repression
Our results suggest that during the transition from a bivalent to
an active state, a subset of genes that retain broad H3K4me3
(G) Top 5 significantMSigDB/GSEA HALLMARK pathways based on bivalent H3K27me3 loci that are lost and gained within ±10 kb TSS-TES of a gene inmNRAS
and mBRAF tumor subtypes.
(H) Genome browser view of ChIP-seq tracks for H3K4me3, H3K27me3, and active transcription (H3K79me2/H3K36me3) on the TWIST1 and ZEB1 genes in
mNRAS and mBRAF melanoma tumor subtypes, isogenic mutant melanocytes, and primary melanocytes from Roadmap.
(I) Boxplot displaying quantile normalized mean RNA expression profiles (log2 transcript per million [TPM]) of the TWIST1 and ZEB1 genes in melanocytes (n = 2)
and melanoma tumor subtypes (NRAS = 4, BRAF = 13, WT = 3) with associated chromatin profiles (top) and in a large cohort of melanocytes (n = 86) and
melanoma tumor subtypes (NRAS = 81, BRAF = 118, WT = 38 [bottom]). p values were calculated using a Wilcoxon test. *p < 0.05; **p < 0.0001.
(J) Genome browser view of ChIP-seq tracks for H3K4me3, H3K27me3, and active transcription (H3K79me2/H3K36me3) on the CDH3 and CDH1 genes in
mNRAS and mBRAF melanoma tumor subtypes, isogenic mutant melanocytes, and primary melanocytes from Roadmap.
(K) Boxplot displaying quantile normalized mean RNA expression profiles (log2 TPM) of the CDH3 and CDH1 genes in melanocytes (n = 2) and melanoma tumor
subtypes (NRAS = 4, BRAF = 13, WT = 3) with associated chromatin profiles (top) and in a large cohort of melanocytes (n = 86) and melanoma tumor subtypes
(NRAS = 81, BRAF = 118, WT = 38 [bottom]). p values were calculated using a Wilcoxon test. *p < 0.05; **p < 0.0001.
See also Figures S3 and S4 and Table S2.
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domains are associated with increased transcriptional activa-
tion; however, this was only observed on a small number of
genes (mNRAS = 89 and pNRAS = 45) (Figure 3G). We consid-
ered that another mechanism of gene activation could be
spreading of the H3K4me3 signal, while gene repression may
be associated with shortening of the broad H3K4me3 domains.
On a genome-wide level and within gene-associated domains
(±10 kb TSS), we observed preferential shortening (<2 kb) of
H3K4me3 peaks in melanoma tumors relative to melanocytes
(Figures 4A and 4B). The majority of genes that displayed short-
ening in metastatic tumors were shared with isogenic mutants
and associated with a decrease in gene expression levels (Fig-
ures 4C–4E; Tables S4 and S5), suggesting broad H3K4me3
shortening is an early event in response to NRAS or BRAF onco-
genic activation and a proxy for transcriptional activity. Pro-
moters harboring some of the broadest H3K4me3 domains
that displayed marked shortening and decreased gene expres-
sion included critical melanocyte-specific cell-identity genes,
such as PMEL (also known asGP100), PAX3,MITF, and TFAP2A
(Seberg et al., 2017) (Figures 4F, 4G, and S4H). During develop-
mental progression, this broad H3K4me3 signature was not pre-
sent in ESCs or germ layer cells (Figures 4H and 4I), indicating
these domains are unique to fully differentiated somatic cells.
Together, these results identify broad H3K4me3 domains as an
epigenetic feature of melanoma progression.
PRC2 complex regulates aberrant bivalent H3K27me3
domains
Trimethylation of H3K27 through an active PRC2 complex
(EZH2, SUZ12, and EED) represses the expression of genes
with acquired, tissue-restricted promoter bivalency (Jadhav
et al., 2016). To determine whether PRC2 members are aber-
rantly expressed in metastatic melanoma, we first investigated
their gene expression in tumor samples using TCGA RNA-seq
data (Cancer Genome Atlas Network, 2015; Colaprico et al.,
2016) from mNRAS (n = 81), mBRAF (n = 118), and mWT (n =
38). Here, NRAS mutant melanomas displayed increased
expression of SUZ12 (p value = 0.037) compared with BRAF
mutant samples (Figures 5A and S5A), and we further observed
an increase of SUZ12 expression (p value = 0.053) in NRAS
mutant melanoma in tumor dataset GSE15605 (Figures 5B and
S5B) (Raskin et al., 2013). Furthermore, immunohistochemistry
(IHC) of tissue microarrays (TMAs) harboring stages III and IV
melanoma samples with annotated NRAS (patients = 7; sam-
ples = 14) and BRAF mutations (patients = 18; samples = 35)
and western blotting analysis of MSTCs revealed that NRAS
mutant, but not BRAF mutant, melanomas highly express
SUZ12 (Figures 5C–5E and S5C–S5E). Consistently, we found
that reducing NRAS levels in NRAS mutant MSTC-2125 using
two different single guide RNAs (sgRNAs) decreased the expres-
sion of SUZ12, but not EZH2 (Figure 5F), further demonstrating
an association between NRAS mutants and SUZ12 expression.
We found that bivalent domains in melanoma associate with
PRC2 members SUZ12 and EZH2, with 759 domains identified
in NRAS mutants and 932 domains in BRAF mutants (Figures
5G and 5H). The majority of PRC2-associated bivalent domains
localized within ±10 kb of a TSS (96.3% in NRAS mutants and
95.6% in BRAF mutants) (Figure 5I), suggesting these bivalent
domains may be functional in regulating target gene expression.
To examine the functional role of PRC2 in modulating bivalent
H3K27me3-associated loci, we tested the impact of a potent
EZH2 inhibitor, GSK-126 (McCabe et al., 2012; Verma et al.,
2012), on these domains. As expected, EZH2 inhibitionmarkedly
decreased the global and site-specific levels of H3K27me3, as
well as bivalent H3K27me3 associated loci, in both NRAS and
BRAF mutant melanomas (Figures 5J–5L). The association of
bivalent H3K27me3 domains with PRC2 and the disruption of
H3K27me3-associated loci through EZH2 inhibition was
observed onmultiple EMT-TFs and critical developmental genes
(Figures S5F–S5H). With these observations, we further postu-
lated that bivalent domains may be functional in regulating the
expression of EMT-TF genes in metastatic melanoma. In breast
cancer, transforming growth factor b (TGF-b) enables the transi-
tion from a bivalent to active state at the ZEB1 promoter, a pro-
cess associated with the removal of H3K27me3 (Chaffer et al.,
2013). In melanoma, inhibiting H3K27me3 through GSK-126
treatment induced a dose-dependent increase of ZEB1 mRNA
expression levels in multiple cell lines, including Malme-3M,
IGR-1, and SK-MEL-28 (Figure 5M). An increase of the TWIST1
gene was further observed in WM266-4 cells in response to
Figure 3. A subset of melanocyte-specific bivalent genes transition to transcriptionally active H3K4me3
(A–D) Scatterplots of peak width (x axis) and height (y axis) from MACS2 broad peak calls (p value 1e5) for H3K4me3 in mNRAS mutant tumors. (B) mBRAF
mutant tumors, (C) mWT tumors, and (D) melanocytes from Roadmap.
(E) Heatmap of H3K4me3, H3K27ac, H3K4me1, and H3K79me2 signal at 10 to +10 kb around TSSs of ensemble genes based on H3K4me3 domain width in
melanoma tumors.
(F) Barplot of bivalent H3K27me3 genes (±10 kb TSS-TES) that are lost in melanocytes and associated with broad or non-broad H3K4me3 in mNRAS, mBRAF,
mWT melanoma tumor subtypes, and isogenic mutant melanocytes.
(G and H) Venn diagram of broad or non-broad H3K4me3 domains overlapping in mNRAS tumors and pNRAS melanocytes and (H) mBRAF tumors and pBRAF
melanocytes.
(I) Boxplot displaying quantile normalizedmean RNA expression profiles of mNRAS (n = 81) andmBRAF (n = 118) tumor subtypes andmelanocytes (n = 86) based
on broad or non-broad H3K4me3-associated genes identified in (G) and (H). p values were calculated using a Wilcoxon test.
(J) Top significant GSEA HALLMARK pathways based on bivalent H3K27me3 genes (±10 kb TSS-TES) that are lost in melanocytes and associated with broad or
non-broad H3K4me3 domains in mNRAS tumor subtypes identified in (G).
(K) Genome browser views of ChIP-seq tracks for H3K4me3, H3K27me3, and active transcription (H3K79me2/H3K36me3) on the SOX9, PDGFA, and MYCN
genes in mNRAS, mBRAF, mWT melanoma tumor subtypes, isogenic mutant melanocytes, and primary melanocytes from Roadmap.
(L) Boxplot displaying quantile normalizedmeanRNAexpression profiles (log2 TPM) of theSOX9,PDGFA, andMYCN genes inmelanocytes (n = 2) andmelanoma
tumor subtypes (NRAS = 4, BRAF = 13, WT = 3) with associated chromatin profiles (top) and in a large cohort of melanocytes (n = 86) and melanoma tumor
subtypes (NRAS = 81, BRAF = 118, WT = 38 [bottom]). p values were calculated using a Wilcoxon test. *p < 0.05; **p < 0.0001.
See also Figure S4 and Table S3.
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GSK-126 treatment, and SNAI1 was activated in Malme-3M
cells, albeit this did not occur in a dose-dependent manner
even at lower concentrations (Figure 5N). A dose-dependent in-
crease of ZEB1 protein levels and an increase of SNAI1 protein
levels were further observed in Malme-3M cells in response to
GSK-126 treatment (Figure S5I). Consistently, we observed a
loss or marked decrease of H3K27me3 on the ZEB1, TWIST1,
SNAI1, SOX9, TGFBI, and PDFGRA promoters upon EZH2 inhi-
bition (Figures 5O and S5F–S5H). With the ability of EZH2 inhibi-
tion to disrupt H3K27me3 onmultiple EMT-TF genes harboring a
bivalent domain, these data suggest genes involved in the switch
to an invasive state may be regulated by shifts of bivalent chro-
matin in melanoma.
EZH2 and MEK combination therapy specifically
abrogates tumor growth in NRAS mutant melanoma
Next, we sought to test the functional and therapeutic implica-
tions of our observations on PRC2-mediated increase in bivalent
H3K27me3 levels in NRAS mutant melanomas. We first tested
whether disruption of the PRC2 complex through EZH2 inhibition
influenced the proliferative or invasive properties inNRASmutant
MSTC cells. While GSK-126 treatment (at 1, 2, and 3 mM) did not
have a significant effect on cellular proliferation (Figures 6A and
6B), we observed a decrease in the invasive capacity of NRAS
mutant cell lines (MSTC-2125 and MSTC-2770), but not in
BRAF mutant cell lines (MSTC-2549 and MSTC-2765) (Figures
6C–6F). As expected, we observed loss in the global levels of
H3K27me3 in both subtypes (Figures 5J, S6A, and S6B). Consis-
tent with GSK-126 results, treatment of NRAS mutant cell lines
with an additional EZH2 inhibitor, 3-deazaneplanocin A (DZNep)
(Miranda et al., 2009), induced a global loss of H3K27me3 levels
and a decrease in their invasive capacity (Figures S6C–S6E).
This is consistent with the effects of bivalent domain reprogram-
ming on mesenchymal driver genes. Since EZH2 inhibition abro-
gated invasion, but not proliferation, we tested whether EZH2 in-
hibitors could be combined with proliferation blocking US Food
and Drug Administration (FDA)-approved MEK inhibitors to block
tumor growth in melanoma. We treated tumors derived from two
NRAS mutant cultures (MSTC-2125 and MSTC-2770) or BRAF
mutant cultures (MSTC-2765 and MSTC-2549) in NUDE mice
(n = 5 per condition) with EZH2 inhibitor GSK-126 (150 mg/kg),
MEK inhibitor (1 mg/kg), or a combination of EZH2 plus MEK in-
hibitors. While monotherapy EZH2i or MEKi only showed modest
effects, the combination treatment of EZH2i and MEKi drastically
reduced the tumor burden of NRASmutant melanoma cells (Fig-
ures 6G and 6H). By contrast, we did not observe a combinatorial
effect of EZH2i plusMEKi on tumor volumes inBRAFmutant mel-
anomas (Figures 6I and 6J). All of these treatments had minimal
effects on the body weights of the treated mice (Figure S6F),
demonstrating low toxicity from these combinatorial treatments.
Importantly, we observed a significant decrease on tumor volume
in BRAF mutants using BRAFV600E inhibitor vemurafenib (Fig-
ure S6G), demonstrating these samples are not inherently resis-
tant to traditional therapies.
To determine whether EZH2 inhibition impacts invasion, we
first checked the lung, liver, and lymph nodes for any nodules
from all the mice that were injected with the EZH2 inhibitor or
vehicle control in MSTC-2125 tumors. Here, we did not find any
evidence for discernible micro or macro metastatic growth in
distant organs potentially due to the duration of the experiment.
To determine whether EZH2 inhibition impacts invasion on amo-
lecular level, we further evaluated the protein levels of invasive
marker vimentin using IHC in vehicle, EZH2, MEK, or EZH2i +
MEKi-treated tumors. Interestingly, we observed a significant
decrease in the number of vimentin-positive cells upon treatment
with EZH2i or EZH2 + MEKi compared with vehicle control (Fig-
ures S6H and S6I), together suggesting that while we didn’t
observe any metastatic events at this time frame, the molecular
events promoting invasion and metastasis are impacted by
EZH2 inhibition. Together, these results suggest inhibition of
PRC2 in combination with MEKi may be a promising therapeutic
strategy for NRAS mutant melanoma patients that harbor
increased PRC2 activity and bivalent H3K27me3 domains.
DISCUSSION
Using combinatorial chromatin state profiling coupled with
mutation, gene expression, and DNA methylation data, we
find that a network of genes encompassing EMT-TF andmelano-
cyte-specific cell-identity genes may be regulated by bivalent
Figure 4. Broad H3K4me3 domain shortening correlates with transcriptional repression
(A) Kernel density estimation plot displaying H3K4me3 peak length change (±2 kb) frommelanocytes tomelanoma tumor subtypes. Number denotesmean length
change in kilobases between melanocytes and melanoma subtype. Asterisk denotes p value < 1e50 between melanoma subtype length changes.
(B) Barplot of broad H3K4me3 promoter associated sites (10 to +10 kb) displaying shortening or lengthening (±2 kb) in mNRAS, mBRAF, and mWT melanoma
tumor subtypes and isogenic mutant melanocytes relative to primary melanocytes from Roadmap.
(C and D) Venn diagram analysis of broad H3K4me3 domains shortening (±2 kb) relative to melanocytes in mNRAS and pNRAS and (D) mBRAF and pBRAF
samples.
(E) Boxplot displaying quantile normalized mean RNA-seq expression profiles from mNRAS (n = 81) and mBRAF (n = 118) melanoma tumor subtypes and
melanocytes (n = 86) based on genes displaying shortening (±2 kb) of broadH3K4me3 domains identified in (C) and (D). p valueswere calculated using aWilcoxon
test.
(F) Genome browser view of ChIP-seq tracks displaying H3K4me3 on thePMEL,PAX3,MITF, and TFAP2A genes inmNRAS,mBRAF, andmWTmelanoma tumor
subtypes, isogenic mutant melanocytes, and primary melanocytes from Roadmap.
(G) Boxplot displaying quantile normalized mean RNA expression profiles (log2 TPM) of the PMEL, PAX3, MITF, and TFAP2A genes in melanocytes (n = 2) and
melanoma tumor subtypes (NRAS = 4, BRAF = 13, WT = 3) with associated chromatin profiles (top) and in a large cohort of melanocytes (n = 86) and melanoma
tumor subtypes (NRAS = 81, BRAF = 118, WT = 38 [bottom]). p values were calculated using a Wilcoxon test. *p < 0.05; **p < 0.0001.
(H) Genome browser view of ChIP-seq tracks for H3K4me3, on the PMEL, PAX3, MITF, and TFAP2A genes in ESC, trophoblast, mesendoderm, mesoderm,
mesenchymal stem cells, endoderm, ectoderm, melanocytes from Roadmap and TCGA tumors, MSTCs, and CCLE cell lines.
(I) Boxplots displaying quantile normalized mean RNA expression profiles (log2 TPM) of the PMEL, PAX3, MITF, and TFAP2A genes in ESC, trophoblast,
mesendoderm, mesoderm, mesenchymal stem cells, endoderm, ectoderm, melanocytes from Roadmap and TCGA tumors, MSTCs, and CCLE cell lines.
See also Figure S4 and Tables S4 and S5.
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H3K27me3 and broad H3K4me3 domains in metastatic mela-
noma. Together, our work provides insight toward four important
conceptual advances regarding the role of the epigenome in
melanoma and its therapeutic implications (Figure 6K). (1) Ge-
netic events such as NRAS or BRAF mutations may utilize spe-
cific chromatin states to bring about transcriptional changes
unique to that genotype. (2) Chromatin state switches involving
bivalent H3K27me3 domains occur on critical mesenchymal
genes associated with a metastatic phenotype, including the
EMT. (3) Exceptionally wide H3K4me3 domains spanning tens
of kilobases associate with pro-metastatic drivers and melano-
cyte-specific cell-identity genes, suggesting roles for this epige-
netic element in melanoma. (4) Blocking invasive ability of
melanoma via EZH2 inhibitors along with proliferative features
using MEK inhibitors may be a key therapeutic principle in
NRAS mutant melanomas. Overall, the current study encom-
passes the most comprehensive dataset from a large number
of well-annotated samples that is useful for identifying principles
of epigenome regulation in melanoma metastasis and sugges-
tions of epigenetic therapies.
Bivalent chromatin domains have primarily been described in
ESCs, in which they control the expression of critical lineage-spe-
cific genes that gain or lose these modifications as cells differen-
tiate toward a particular phenotype (Bernstein et al., 2006; Voigt
et al., 2013). Innormal cells, bivalentmarksare also foundat genes
with roles specific to the development of those tissues.Hence, is it
plausible these genes were active during organogenesis and an
aberrant TF or epigenetic modification can leave them vulnerable
to transcription in adult cells. In the context of melanocyte devel-
opment, migratory neural crest cells undergo an initial EMT to
break away from the neural fold and move to distant regions of
the embryo (Baker et al., 1997; Sinnberg et al., 2018). This cellular
plasticity, or phenotype switching, allowsmelanocytes to emerge
amidst a myriad of other signaling pathways by quickly activating
and repressing key regulatory genes, including EMT-TFs. Inmela-
noma, the concept of phenotype switching (proliferative to inva-
sive) has been reported, and various EMT-TFs are critical for this
process (Caramel et al., 2013; Goding, 2000; Li et al., 2015).
Although melanocytes are not part of the epithelial lineage, upon
activation ofBRAF orNRAS oncogenes, the EMT-TF network un-
dergoes a reorganization that is associated with the upregulation
of ZEB1 and TWIST1, the loss of CDH1, increased invasion, and
poor prognosis in melanoma patients (Caramel et al., 2013).
In this study, we observed bivalent H3K27me3 domains
display dynamic changes and associated gene expression pat-
terns on core members of the EMT-TF network (ZEB1, TWIST1,
SNAI1, TGFBI, CDH3, and CDH1) during the transition from
ESCs > melanocytes > isogenic mutant melanocytes > metasta-
tic melanoma. All of the core EMT-TF genes identified (with the
exception of SNAI1) display losses and gains of bivalent
H3K27me3 upon isogenic activation of NRAS and BRAF, indi-
cating this switch occurs early in response to mitogen-activated
protein kinase (MAPK) misregulation, and these genes remain
active during metastasis. In addition to EMT-TFs, integration of
melanocyte-specific bivalent genes that transition to transcrip-
tionally active H3K4me3 domains (and lose H3K27me3 in tu-
mors) revealed NRAS mutant-associated broad domains (>4
kb) were enriched on genes critical for neural crest migration
and the switch to an invasive state (SOX9, POU3F2, MYCN,
PDGFRA, and PDGFA) (Caramel et al., 2013; Cheng et al.,
2015; Li et al., 2015; Simmons et al., 2017; Theveneau and
Mayor, 2012), further indicating that melanoma tumor progres-
sion may resemble a reactivated developmental program
mediated by bivalent switches. Since metastasis involves
several cell-fate transitions during its progression from the pri-
mary site to colonization, which likely use a transcriptional cir-
cuitry consisting of different proliferative or invasive genes, it is
plausible shifts involving bivalent chromatin states could be
favored as the preferred mode of gene regulation for EMT-TFs
during the switch to a metastatic phenotype.
Figure 5. The PRC2 complex regulates aberrant bivalent H3K27me3 domains
(A) Boxplot displaying quantile normalized mean RNA expression profiles (log2 TPM) for the SUZ12 gene in melanoma tumor subtypes (NRAS = 81, BRAF = 118,
WT = 38) from the TCGA dataset.
(B) Boxplot displaying microarray profiles (log2) for the SUZ12 gene in melanoma tumor subtypes (normal skin = 16, NRAS = 8, BRAF = 28, WT = 22) from the
GSE15605 dataset.
(C) Boxplot displaying H-SCORES from SUZ12 immunohistochemistry staining in patient TMA harboring anNRASmutation (patients = 7; samples = 14) or BRAF
mutation (patients = 18; samples = 35). p values were calculated using a t test based on H-SCORES in each mutational subtype.
(D and E) Western blotting analysis and (E) quantification for SUZ12 and EZH2 in MSTC harboring an NRAS or BRAF mutation. Relative density was quantified
using ImageJ software, and the values of the target proteins were normalized to b-Actin. The results are representative of three independent biological replicates.
Error bars represent mean ± SEM.NRAS and BRAFmutant MSTCswere run on the same gel and cropped for publication as two additional non-MSTCs were ran
together.
(F) Western blotting analysis for NRAS, SUZ12, EZH2, and b-Actin in NRAS mutant MSTC-2125 expressing scrambled or two different sgRNAs targeting the
NRAS gene.
(G and H) Venn diagram analysis of bivalent H3K27me3-associated loci in NRAS mutant and (H) BRAF mutant melanoma samples overlapping with PRC2
complex members SUZ12 and EZH2 in ESCs.
(I) Genomic localization of bivalent H3K27me3 + PRC2 complex associated loci.
(J) Western blotting analysis for H3K27me3 in MSTC harboring an NRAS mutation treated for 14 days with GSK-126 or DMSO.
(K) Barplot displaying total number of H3K4me3 and H3K27me3 associated loci in Malme-3M cells treated for 14 days with GSK-126 or DMSO.
(L) Venn diagram analysis of bivalent H3K27me3-associated loci in Malme-3M cells treated for 14 days with GSK-126 or DMSO.
(M) qRT-PCR for ZEB1 in Malme-3M, IGR-1, and SK-MEL-28 cell lines treated for 14 days with GSK-126 or DMSO. p values were calculated using a t test.
(N) qRT-PCR for TWIST1WM2664 cell lines and SNAI1 in Malme-3M cell lines treated for 14 days with GSK-126 or DMSO. p values were calculated using a t test.
(O) Genome browser view of ChIP-seq tracks for SUZ12, EZH2, H3K4me3, and H3K27me3 in ESCs; H3K4me3 and H3K27me3 in melanocytes; mNRAS and
mBRAF tumors; representative NRAS mutant MSTCs (MSTC-2125, MSTC-2770, MSTC-2495); and BRAF mutant MSTCs (MSTC-2549, MSTC-2765, MSTC-
2357); and in Malme-3M cells treated for 14 days with GSK-126 or DMSO on the ZEB1, TWIST1, SNAI1, and SOX9 genes.
See also Figure S5.
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In contrast to genes that lose bivalency and retain H3K4me3,
the majority of broad H3K4me3 domains (>4 kb) displayed
markedshortening inmetastaticmelanomatumors relative tome-
lanocytes. A similar observation in NRAS and BRAF isogenic
mutant melanocytes suggests this is an early event in response
to MAPK activation. However, unlike bivalent H3K27me3 do-
mains, broad H3K4me3 shortening was not associated with a
specific mutational subtype (NRAS or BRAF). Previous studies
have demonstrated broad H3K4me3 domains are associated
with increased gene expression and tumor-suppressor gene
regulation (Benayoun et al., 2014; Chen et al., 2015; Dahl et al.,
2016). Broad domains that are conserved across normal cells
may mark a set of pan-cancer tumor suppressors, whereas cell-
type-specific broad H3K4me3 peaks are associated with cell-
identity genes (Chen et al., 2015). In melanoma, we found that
promoters harboring some of the broadest H3K4me3 domains
were associated with melanocyte cell-identity genes known to
bedownregulatedduring theswitch toan invasive state, including
PMEL (aka GP100), PAX3, MITF, and TFAP2A (Denecker et al.,
2014; Goding, 2000; Kemper et al., 2014; Levy et al., 2006; Li
et al., 2015; Seberg et al., 2017). The broad H3K4me3 signature
was not present in ESCs or germ cells, but instead specifically
gained in melanocytes (with the exception of PAX3 in ectodermal
cells), suggesting broad H3K4me3 domains mark cell-identity
genesnecessary for normalmelanocyte function that are lost dur-
ing oncogenic activation. Importantly, further investigation is
needed to determine whether histone methyltransferases
responsible for regulating the broad H3K4me3 signal, such as
KMT2D in medulloblastoma (Dhar et al., 2018), are functional in
melanoma and can be targeted therapeutically.
Mechanisms governing bivalent promoters include histone
methyltransferases such as PRC2 (EZH2, SUZ12, and EED)
(Ku et al., 2008; Voigt et al., 2013). Studies in normal cells sug-
gest tissue-specific mechanisms recruit PRC2 to place
H3K27me3 at genes in order to avoid unwanted mRNA expres-
sion (Jadhav et al., 2016). In melanoma tumors, EZH2 and
H3K27me3 are predominantly expressed at the invasion front
and have been linked to an invasive, EMT-associated phenotype
(Hoffmann et al., 2020; Shields et al., 2017; Zingg et al., 2017). In
this study, we observed NRASmutant melanomas (a highly met-
astatic and aggressive phenotype [Devitt et al., 2011; Jakob
et al., 2012; Thumar et al., 2014]) harbor increased bivalent
H3K27me3 domains and highly express core PRC2 members
SUZ12 and EZH2. The high co-localization of bivalent
H3K27me3 with SUZ12 and EZH2 on multiple EMT-TF genes
suggests these domains may represent functional chromatin el-
ements. Indeed, the ability to active the expression of EMT-TFs
by modulating bivalent chromatin structure using EZH2 inhibi-
tors demonstrates some of these domains are functional in can-
cer. Importantly however, further investigation is needed to
determine what other active modifications or TFs regulate these
genes, and whether their activation through bivalent modulation
can drive an invasive phenotype.
Recently, epigenetic drugs targeting EZH2 have been suc-
cessfully applied in various preclinical models and are rapidly
progressing into clinical trials. For example, a recent clinical trial
in patients with urothelial cancer demonstrated synergistic effect
of EZH2 treatment and anti-PD1 therapy (NCT03854474). In mel-
anoma cells, inhibition of EZH2 activity affects their invasive ca-
pacity and counteracts tumor growth and metastatic spread
in vivo (Zingg et al., 2015). Here, we found that EZH2 inhibition
(GSK-126) decreased H3K27me3 expression, reduced the inva-
sive capacity, and markedly inhibited tumor burden specifically
in NRAS mutant melanoma cultures, but not BRAF mutant cul-
tures, in combination with MEK inhibitor. MEK inhibitor is an
FDA-approved therapy in metastatic melanoma and remains a
prominent therapy in NRAS mutant patients (Boespflug et al.,
2017). However, the responses are limited in majority of the
treated patients (Devitt et al., 2011; Hoffmann et al., 2020; Jakob
et al., 2012; Thumar et al., 2014). Our data suggest that inhibition
of proliferation by MEKi (Johnson and Sosman, 2013; Zipser
et al., 2011) along with inhibition of the invasive/mesenchymal
phenotype by EZH2i could be the biological explanation for the
observed effect of combinatorial therapy in NRAS mutant mela-
noma. Thus, these observations provide a conceptual advance
for design of future therapeutics to focus on targeting these
two processes in NRAS mutant melanomas.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
Figure 6. EZH2i and MEKi combination therapy decreases tumor burden in NRAS mutant melanoma
(A and B) Proliferation assay representing confluence percentage inNRASmutant MSTC cell lines 2125 and (B) 2770 treated for 14 days with GSK-126 or DMSO.
Error bars represent mean ± SEM.
(C and D) Boyden chamber invasion assay in NRAS mutant MSTC cell lines 2125 and (D) 2770 treated for 14 days with GSK-126 or DMSO. p values were
calculated using a t test. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars represent mean ± SEM.
(E and F) Boyden chamber invasion assay inBRAFmutantMSTC cell lines 2549 and (F) 2765 treated for 14 days withGSK-126 or DMSO. p valueswere calculated
using a t test. *p < 0.05. Error bars represent mean ± SEM.
(G–J) Tumor volume curves for NRASmutant melanoma cultures (G) MSTC-2125 and (H) MTSC-2770 or BRAFmutant melanoma cultures (I) MSTC-2549 and (J)
MSTC-2765, upon treatment with vehicle, MEK inhibitors (trametinib), EZH2 inhibitor (GSK-126), and a combination of MEK and EZH2 inhibitors (trametinib +
GSK-126) (n = 5 for each arm). p values represent pairwise t test comparison between the experimental arm to vehicle treatment. *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. Error bars represent mean ± SEM.
(K) Model explaining potential mechanism in which switches of bivalent H3K27me3 domains on EMT-TFs, and shortening of H3K4me3 domains on melanocyte-
specific cell-identity genes, control their expression during the switch from a proliferative to an invasive phenotype in metastatic melanoma. EMT-TFs and
melanocyte-specific genes identified here are differentially expressed in alternate phenotypic states, with ZEB1, TWIST1, SNAI1, SOX9, PDGFRA, and PDGFA
displaying high expression in a mesenchymal/invasive phenotype and CDH1, MITF, PAX3, PMEL, and TFAP2A displaying high expression in melanocytes/
proliferative phenotype.
See also Figure S6.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti-EZH2 (Cell Signaling; 5246S) Cell Signaling CAT#5246S; RRID:AB_10694683
anti-SUZ12 Active Motif CAT#39057; RRID:AB_2614929
anti-ZEB1 Millipore Sigma CAT#ABD53; RRID:N/A
H3K4me3 Abcam CAT#ab8580; RRID:AB_306649
H3K4me1 Abcam CAT#ab8895; RRID:AB_306847
H3K9me3 Abcam CAT#ab8898; RRID:AB_306848
H3K27ac Abcam CAT#ab4729; RRID:AB_2118291
H3K27me3 Abcam CAT#ab6002; RRID:AB_305237
H3K79me2 Abcam CAT#ab3594; RRID:AB_303937
anti-H3 Cell Signaling CAT#4499S; RRID:AB_10544537
anti-Beta-actin Cell Signaling CAT#4967S; RRID:AB_330288
anti-SNAI1 Abcam CAT# ab216347 RRID:N/A
anti-NRAS Abcam CAT#ab77392 RRID:AB_1524048
anti-Vimentin Cell Signaling CAT#5741 RRID:AB_10695459
Anti-rabbit IgG, horseradish
peroxidase (HRP)-linked
Cell Signaling CAT#7074S; RRID:AB_2099233
Horse anti-mouse IgG, HRP-linked Cell Signaling CAT#7076S RRID:AB_330924
Chemicals, peptides, and recombinant proteins
GSK-126 1346574-57-9, 5 mg Caymen Chemical CAT#NC0761027
GSK-126, 500mg MedChemExpress CAT# HY-13470
Vemurafenib MedChemExpress CAT# HY-12057
Trametinib MedChemExpress CAT# HY-10999A
3-Deazaneplanocin A Caymen Chemical CAT#102052-95-9




miniProtease inhibitor Roche CAT#11836153001
Dynabeads Protein G for Immunoprecipitation Thermo Fisher CAT#10009D
Solid-Phase Reversible Immobilization (SPRI)
beads; Reagent, SPRIselect, 450mL
Beckman-Coulter CAT#B23319
Dulbecco’s Phosphate Buffered
Saline (DPBS) (Ca2+- and Mg2+-free)
Millipore Sigma CAT#D8537-500ML
HBSS (Ca2+- and Mg2+-free) Thermo Fisher CAT#88284
Invitrogen UltraPure 0.5M EDTA, pH 8.0 Thermo Fisher CAT#15575020
L-Glutamine (200 mM) Millipore Sigma CAT#25030081
HEPES solution Millipore Sigma CAT#H0887-100ML
Sodium dodecyl sulfate (SDS) Sigma-Aldrich CAT#74255
Lithium Chloride Sigma-Aldrich CAT#746460
Sodium Chloride Sigma-Aldrich CAT#S7653
Tris-HCL 1M pH 8.0 Teknova CAT#T1080
Glycine Sigma-Aldrich CAT#G8898
Pierce 16% Formaldehyde (w/v),
Methanol-free
Thermo Fisher CAT#28908
Bovine Serum Albumin – IgG free Millipore Sigma CAT#A2058 5G
RNase A Invitrogen CAT#12091021
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Proteinase K Invitrogen CAT#100005393
RIPA buffer Boston BioProducts CAT# BP-115
2x Laemmli buffer Bio-Rad CAT#1610737
4-20% Criterion TGX Stain-Free gels Bio-Rad CAT#5678094
Amersham ECL Western Blotting
Detection Reagent
GE Healthcare CAT#RPN2106
SuperSignal West Pico Plus
Chemiluminescent substrate
Thermo Fisher CAT#34577
SuperSignal West Dura Extended
Duration substrate
Thermo Fisher CAT#34075
Restore Western Blot stripping buffer Thermo Fisher CAT#21063
Critical commercial assays
NEBNext Multiplex Oligos (index
primer – Set1)
New England Biolabs CAT#E7335L
NEBNext Multiplex Oligos (index
primer – Set2)
New England Biolabs CAT#E7500L
NEBNext Ultra II DNA Library
Prep Kit for Illumina
New England Biolabs CAT#E7645L
High Sensitivity D1000 Reagents Agilent Technologies CAT#5067-5585
Invitrogen Qubit dsDNA HS Assay Kit Thermo Fisher CAT#Q32851
TruSeq DNA LT Sample Prep Kit Illumina CAT# FC-121-2001 and FC-121-2002
DynaMag – 96 Side Skirted Invitrogen CAT#120.27
Matrigel-coated well inserts Corning CAT#08774122
Deposited data
Raw and analyzed data This paper GSE134043
Human reference genome (UCSC hg19) Illumina iGenome http://bowtie-bio.sourceforge.
net/index.shtml
Ensemble annotated human genome features Ensembl https://genome.ucsc.edu/cgi-bin/hgTables
Experimental models: Cell lines
Melanoma Short Term Cultures This paper N/A
Experimental models: Organisms/strains
Mouse: Crl:NU(Ico)-Foxn1nu Charles River Strain code: 620
Software and algorithms




Genome alignment: Bowtie (v1.1.2) Langmead et al., 2009 http://bowtie-bio.sourceforge.net/index.shtml
Duplicate read removal: SAMBLASTER Faust and Hall, 2014 https://github.com/GregoryFaust/samblaster
Downsampling: samtools (v1.5) Li et al., 2009 http://samtools.sourceforge.net/
ChIP-seq library visualization:
deepTools (v2.4.0)
Ramı́rez et al., 2016 https://deeptools.readthedocs.io/
en/develop/
ChIP-seq peak calling: Model-based analysis
of ChIP-seq (MACS) (v1.4.2) and (v2.1.0)
Zhang et al., 2008 http://liulab.dfci.harvard.edu/MACS/
00README.html
Galaxy/Cistrome Liu et al., 2011 http://cistrome.org/ap/root
Gene body heatmaps and average
density plots: ngs.plot
Shen et al., 2014 https://github.com/shenlab-sinai/ngsplot
Chromatin state patterns: ChromHMM Ernst and Kellis, 2012 http://compbio.mit.edu/ChromHMM/
Gene Set Enrichment Analysis (MSigDB) Subramanian et al., 2005 https://www.gsea-msigdb.org/gsea/
msigdb/index.jsp
RStudio https://www.rstudio.com/
Bedtools Quinlan and Hall., 2010 https://bedtools.readthedocs.io/en/latest/
Bedops Neph et al., 2012 https://bedops.readthedocs.io/en/latest/






Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kunal Rai
(krai@mdanderon.org).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The ChIP sequencing data has been deposited in the NCBI GEO BioProject database with the following accession number
GSE134043. ChIP-seq data for histone modifications in ESCs, germ cells and melanocytes were downloaded from ftp://ftp.ncbi.
nlm.nih.gov/pub/geo/DATA/roadmapepigenomics/. ChIP-seq data for SUZ12 and EZH2 was downloaded from the NCBI GEO Bio-
Project database with the following accession number GSE29611. Code used in this study is available on https://rpubs.com/cjt5 and
https://github.com/sccallahan/ChromXploreR.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Melanoma tumors were obtained from the Melcore tumor bank at MD Anderson Cancer Center as per an approved Institutional Re-
view Board protocol (IRB #PA12-0305). The details of the patient samples are available in Table S1.
Animals
Female mice (strains: Crl:NU(Ico)-Foxn1nu Charles river, strain code 620) were purchased, bred in house, and maintained at 72F ±
2F on a 12h light/dark cycle. Four- to six-week-old aged females were randomly assigned with five mice housed together per cage.
Animals were provided ad libitium access to food and water. All the animal studies were performed as per an approved Institutional
Animal Care and Use Committee protocol (IACUC #00001411-RN01).
Cell lines
Melanoma short term cultureswere generated frommetastatic tumor specimens aspart of the Adoptive T cell TherapyClinical Program
at the University of Texas, MD Anderson Cancer Center (LAB06-0755 and 2004-0069), as previously described (Oba et al., 2018;
Besser et al., 2009; Park et al., 2017). Briefly a tumor specimen frommetastatic tumor was collected and incubated with an enzymatic
digestion cocktail (0.375% collagenase type I, 75 mg/ml hyaluronidase and 250 U/mL DNase I) in tumor digestion medium (RPMI,
10 mM of HEPES, 1x Penicillin-Streptomycin and 20 ug/mL of Gentamicin; GIBCO/Invitrogen) in a humidified incubator at 37C
with 5%CO2 and with a gentle rotation for 2-3h to obtain a single cell suspension. The tumor digest was filtered through a 70-mm filter,
washed, and re-suspended in a serum free media, which was then plated in one well of a 6-well culture plate and incubated at 37C.
After 24h, the media was replaced with fresh tumor media, comprised of RPMI with GlutaMAX, 10% FBS, Penicillin/Streptomycin,
Gentamicin, b -mercaptoethanol (50 uM, GIBCO/Invitrogen), HEPES (10 mM), and insulin-selenium-transferin (5 ug/ml, GIBCO/Invitro-
gen). Cells were grown in enriched DMEM/F12 culture media (GIBCO/Invitrogen) supplemented with all growth factors including 10%
FBS, sodium pyruvate (1mM), insulin-selenium-transferin, MycoZap-PR (Lonza), HEPES (10mM) and b-Mercaptoethanol. Once
enough cells were grown, the purity of the tumor was tested using a melanoma tumor surface marker (MCSP-1) by flow cytometry.
Cultureswere deemed establishedwhen the cells stained positive for amelanoma tumormarker (MCSP-1) and negative for a fibroblast
marker (CD90). Appropriate serum starvingwas performed to eliminate fibroblasts. All cell lines were tested for mycoplasma usingMy-
coAlert detection kit (Lonza), and fingerprinted by STR fingerprinting, and validated by comparing with matched blood samples. A few
passages after a pure tumor line was established, the cells were cryopreserved and kept in stocks in liquid nitrogen until use.
Isogenic mutant melanocytes
BRAFV600E orNRASQ61Kmelanocytes were generated as described in Fiziev et al. (2017), Garraway et al. (2005), and Rai et al. (2015).
Briefly, normal melanocytes were immortalized by TERT expression and partially-transformed by overexpression of dominant nega-




ChIP assays were performed as described previously (Terranova et al., 2018). Briefly, for tumor samples 50mg of tissue (~7mg/IP)
were manually dissociated in 2mL of Hanks Balanced Salt Solution (HBSS) using a sterile razor blade. An additional 8mL of HBSS
was added and tissue was further disassociated using a MACS homogenizer with the follow cycles; h_tumor_01.01, h_tumor_02.01,




h_tumor_03.01 and m_heart_02.01. For cell lines, 23 107 cells were harvested by scraping. Tumors and cell lines were cross-linked
with 1% (wt/ vol) formaldehyde for 10 min at 37Cwith shaking. After quenching with 150 mM glycine for 5 min at 37Cwith shaking,
cells were washed twice with ice-cold PBS and frozen at 80C for further processing. Cross-linked pellets were thawed and lysed
on ice for 30min in ChIP harvest buffer (12mMTris-Cl, 13PBS, 6mMEDTA, 0.5%SDS) with protease inhibitors (Sigma). Lysed cells
were sonicated with a Bioruptor (Diagenode) to obtain chromatin fragments (~200–500 bp) and centrifuged at 15,0003 g for 15 min
to obtain a soluble chromatin fraction. In parallel with cellular lysis and sonication, antibodies (5 mg/33 106 cells) were coupled with
30 mL of magnetic protein G beads in binding/blocking buffer (PBS + 0.1% Tween + 0.2%BSA) for 2h at 4Cwith rotation. Antibodies
used for ChIP included anti-H3K4me3 (Abcam; ab8580), anti-H3K4me1 (Abcam; ab8895), anti-H3K27ac (Abcam; ab4729), anti-
H3K79me2 (Abcam; ab3594), anti-H3K27me3 (Abcam; ab6002) and anti-H3K9me3 (Abcam; ab8898). Soluble chromatin was diluted
five times using ChIP dilution buffer (10 mM Tris-Cl, 140 mMNaCl, 0.1%DOC, 1% Triton X, 1 mMEDTA) with protease inhibitors and
added to the antibody-coupled beads with rotation at 4C overnight. After washing, samples were treated with elution buffer (10 mM
Tris-Cl, pH 8.0, 5 mM EDTA, 300 mM NaCl, 0.5% SDS), RNase A, and Proteinase K, and cross-links were reversed overnight at 37.
Immune complexes were then washed five times with cold RIPA buffer (10mM Tris–HCl, pH 8.0, 1mM EDTA, pH 8.0, 140mM NaCl,
1% Triton X-100, 0.1% SDS, 0.1% DOC), twice with cold high-salt RIPA buffer (10mM Tris–HCl, pH 8.0, 1mM EDTA, pH 8.0, 500mM
NaCl, 1% Triton X-100, 0.1% SDS, 0.1% DOC), and twice with cold LiCl buffer (10mM Tris–HCl, pH 8.0, 1mM EDTA, pH 8.0, 250mM
LiCl, 0.5% NP-40, 0.5% DOC). ChIP DNA was purified using AMPure XP beads (Agencourt) and quantified using the Qubit 2000 (In-
vitrogen) and Bioanalyzer 1000 (Agilent). Libraries for Illumina sequencing were generated following the New England BioLabs (NEB)
Next Ultra DNA Library Prep Kit protocol. A total of 10 cycles were used during PCR amplification for the generation of all ChIP-seq
libraries. Amplified ChIP DNAwas purified using double-sided AMPure XP to retain fragments (~200–500 bp) and quantified using the
Qubit 2000 and Bioanalyzer 1000 before multiplexing.
ChIP-seq data processing
Raw fastq reads for all ChIP-seq experiments were processed using a snakemake based pipeline https://github.com/craz
yhottommy/pyflow-ChIPseq. Briefly, raw reads were first processed using FastQC (https://www.bioinformatics.babraham.ac.uk/
projects/fastqc/) and uniquely mapped reads were aligned to the hg19 reference genome using Bowtie version 1.1.2 (Langmead
et al., 2009). Duplicate reads were removed using SAMBLASTER (Faust and Hall, 2014) before compression to bam files. To directly
compare ChIP-seq samples uniquely mapped reads for each mark were downsampled per condition to 18 million, sorted and in-
dexed using samtools version 1.5 (Li et al., 2009). To visualize ChIP-seq libraries on the IGV genome browser, we used deepTools
version 2.4.0 (Ramı́rez et al., 2016) to generate bigWig files by scaling the bam files to reads per kilobase per million (RPKM). Super
ChIP-seq tracks were generated by merging bam files from each cancer type, sorting and indexing using samtools and scaling to
RPKM using deepTools.
Chromatin state analysis
ChromHMM (Ernst and Kellis, 2012) was used to identify combinatorial chromatin state patterns based on the histone modifications
studied. Normalized bam files were converted to bed files and binarized at a 1000bp resolution using the BinarizeBed command. We
specified that ChromHMM should learn a model based on 18 chromatin states. As we considered models between 2 and 30 chro-
matin states, we annotated an 18-state model since it is large enough to identify non-redundant functional elements encompassing
canonical chromatin states that were not captured using lower state models. To determine chromatin state differences between
different groups we used a two-step process. First, using the segmentation calls from the ChromHMM output the entire genome
is divided into non-overlapping windows of 10 Kb. We next count the number of times a chromatin state is observed in each of
the 10 Kb windows and obtain a frequency matrix for each state in the ChromHMMmodel (E1-E18). In the second step, low variable
genomic loci are removed from the frequencymatrix and significant differences between two groups of samples types are calculated
by using a nonparametric Mann Whitney Wilcoxon test with a P value < 0.05 for each state separately.
Correlation of copy number from ChIP-seq and SNP array
SKCM TCGA copynumber data were downloaded by TCGAbiolinks (Colaprico et al., 2016). Copy number analysis for ChIPseq was
carriedout usingcopywriter (Kuilmanet al., 2015),whichusesoff-target reads for accurate copynumberdetection. TheChIP-seq input
fileswereused,which represent low-passwholegenomesequencingdatasets.Binsizeof 200kbwasused for analysis. Thecopynum-
ber of each genewas determined by overlapping the geneswith the segmentation files fromChIPseq andSNParray, respectively. The
Pearson correlation of the copy number of all genes among samples was calculated and plotted in heatmap by ComplexHeatmap.
Correlation of RNA expression and chromatin state data
SKCM TCGA RNaseq data were downloaded by TCGAbiolinks (Colaprico et al., 2016). TPM (transcript per million) value was
calculated from raw counts by scaling to the gene length first and then the library size. For each gene in a sample, the transcription
start site is overlapped with the chromatin state segmentation file to determine the state of that gene. The expression values (TPM)
for all genes and all samples are then combined and spilt by categories (18) of chromatin states. A boxplot is plotted for each
chromatin state.




Correlation of DNA methylation and chromatin state data
SKCM TCGA 450k DNA methylation data were downloaded by TCGAbiolinks (Colaprico et al., 2016). For each sample and each
chromatin state segmentation bin, the average of beta values from the DNA methylation data were calculated for each bin. The
average values of all bins from all samples are combined and then split by categories (18) of chromatin states. A boxplot is plotted
for each chromatin state.
Identification and visualization of ChIP-seq associated loci
We used Model-based analysis of ChIP-seq (MACS) version 1.4.2 (Zhang et al., 2008) peak calling algorithm to identify H3K4me3 (p
value of 1e-5) and MACS version 2.1.0 to identify H3K27me3 (p value of 1e-5) enrichment over ‘‘input’’ background. Bivalent sites
were identified by overlapping H3K4me3 with H3K27me3 or H3K9me3 by a minimum of 1bp using intersectBed (Quinlan and
Hall, 2010). Identification of H3K27me3 peaks in isogenic mutant melanocytes were identified using MACS version 1.4.2. Bivalent
polycomb-heterochromatin regions were identified by overlapping the H3K4me3+H3K27me3 output with H3K9me3 by a minimum
of 1bp. Common sites were identified using bedops (Neph et al., 2012) with the following command; cat *bed | sort-bed - | bedmap–
count–echo–delim ‘yt’ - | uniq | awk ‘$1 > = x’ | cut -f2- > samplename_common.bed. This was based on peaks present in BRAF = 7/
13, NRAS = 2/4, WT = 2/3, MSTC = 5/10, CCLE = 8/16 andmelanocytes = 2/2 samples. Final peaksets used for downstream analysis
were generated using mergeBed. Unique BRAF, NRAS, WT and melanocyte peaks for bivalent domains were identified using the
concatenate, cluster and subtract tools from the Galaxy/Cistrome web-based platform (Liu et al., 2011). To identify sites that
were bivalent in melanocytes but active in melanoma tumors, and visa-versa, common H3K27me3 sites were subtracted from the
opposing bivalent site in each comparison.
Identification of broad H3K4me3 domains
BroadH3K4me3 domains for all sampleswere identified usingMACS2.1.0with the broad setting (p value of 1e-5) followed bymerging
adjacent peakswithin 1kb usingmergeBed (Quinlan andHall, 2010; Subramanian et al., 2005).We determined the optimal distance to
merge adjacent peaks based on the number of broad H3K4me3 domains at distance thresholds between 1kb through 10kb in each
mutational subtype.BroadH3K4me3domainswere further classified aspeaks that extendedat least 4x (> 4kb) beyond that of a typical
H3K4me3 domain (0.2kb-1kb). Final peaksets for common sites broad and non-broad H3K4me3 and H3K27me3 domains were
defined as in identification and visualization of ChIP-seq associated loci (BRAF = 7/13, NRAS = 2/4,WT = 2/3 andmelanocytes = 2/2).
Assigning associated loci to genes
A list of Ensembl genes was obtained from the UCSC Table browser (http://genome.ucsc.edu/). Promoters were defined as ± 10kb
from the transcription start site (TSS) and genic regions were identified as +10kbTSS to the transcription end site (TES). Peaks were
assigned to genes if they overlapped the promoter or genic region by a minimum of 1bp using intersectBed. Gene body heatmaps
and average density plots were generated using ngs.plot (Shen et al., 2014).
Gene set enrichment analysis
Gene Set Enrichment Analysis (GSEA) was performed using GSEA/MsigDB (Subramanian et al., 2005) HALLMARK and KEGG path-
ways based on ensemble gene lists frompeakswithin10kb-TES for bivalent domains and ± 10kbTSS for broadH3K4me3 domains.
All pathways are significant based on FDR q-value.
RNA-sequencing data processing
For TCGA data, raw counts were obtained from TCGAbiolinks (Colaprico et al., 2016) in R (https://www.rstudio.com/) and trans-
formed to TPM. For the melanoma tumor data in addition to TCGA, raw microarray expression levels were obtained from
GSE15605. For Roadmap data, raw counts were obtained from http://www.roadmapepigenomics.org/ and transformed to TPM.
For melanocyte data in addition to Roadmap, raw counts were obtained from PRJNA421623 and SRP002621. For all RNA-seq box-
plots based on count data, gene expression values were normalized using the quantile normalization function in R.
Proliferation assays
Cell proliferation was measured and quantified using IncuCyte ZOOM system (Essen Biosciences). Briefly, after 14 days of GSK-126
(1 mM, 2 mM, 3 mM) or DMSO treatment melanoma short-term cultures MSTC-2125 andMSTC-2770 cells were seeded at a density of
5,000 cells per well in 96-well plates. Cell proliferation was measured for 155h and media for GSK-126 and DMSO treatment was
replaced every third day. Cell proliferation is plotted as confluence percentage.
Boyden Chamber invasion assays
Boyden Chamber assays were performed according to manufacturer’s protocol after 14 days of GSK-126 (1 mM, 2 mM, 3 mM) or
DMSO treatment of melanoma short-term cultures. For 3-Deazaneplanocin A (DZNep), MSTC-2125 were treated for 14 days
(1 mM, 2 mM, 3 mM) and MSTC-2770 were treated for 10 days (1 mM, 2 mM). Briefly, cells were washed 3-times with ‘‘empty’’ media
(serum and antibiotic free) and 100,000 cells were subjected to Matrigel-coated well inserts (08774122, Corning). Growth media was
used as a chemoattractant for 24h in Matrigel wells. For reference wells 100,000 cells were plated in growth media. Cells in Matrigel




and reference wells were washed with 1% PBS and incubated with 10% formalin for 10 minutes. Cells were washed again with 1%
PBS and incubated in crystal violet staining for 10 minutes. For quantitation, the invaded cells and the control plated cells were de-
stained in 10% acetic acid for 15 minutes and calorimetry was performed at 590nM. The ratio of invaded cells to control cells was
plotted to graph relative invasion.
Immunoblot analysis
Melanoma short-term cultures (1 x107 cells) were washed with ice-cold PBS then lysed for 30 minutes at 4C with agitation in RIPA
buffer (Boston BioProducts; BP-115) supplemented with a Roche cOmplete, Mini, EDTA-free protease inhibitor cocktail (Millipore
Sigma; 11836170001). Malme-3M cells were treated for 14 days with GSK-126 (1 mM, 2 mM, 3 mM) or DMSO before lysis. Lysate
was centrifuged at 4C for 15minutes at 15,000rpm. The pellet was discarded and protein was quantified using BCA assay. Samples
were supplemented with 2x Laemmli buffer (Bio-Rad; 1610737) and 2-mercaptoethanol, heated for 5 min at 95C and loaded on
4%–20% Criterion TGX Stain-Free gels (Bio-Rad; 5678094). Protein expression was examined by western blot using anti-EZH2
(Cell Signaling; 5246S), anti-SUZ12 (Active Motif; 39057), anti-ZEB1 (Millipore Sigma; ABD53), anti-SNAI1 (ab216347), anti-NRAS
(ab77392), anti-H3 (CST; 4499S) Beta-actin (CST; 4967S), goat anti-rabbit IgG-HRP (CST; 7074S) and horse anti-mouse IgG-HRP
(CST; 7076S). Reactive bands were detected by Amersham ECL Western Blotting Detection Reagent (RPN2106, GE Healthcare),
SuperSignal West Pico Plus Chemiluminescent substrate (Thermo; 34577) or SuperSignal West Dura Extended Duration substrate
(Thermo; 34075). The membranes were reprobed after incubation in Restore Western Blot stripping buffer (Thermo; 21063). ImageJ
software was utilized to measure image densitometry of bands as previously described (Janes, 2015). Western blot results were
representative of at least three independent biological replicates.
Acid extraction of histones
Melanoma short-term cultures (1 x107 cells) were treated for 14 days with GSK-126 (1 mM, 2 mM, 3 mM) or DMSO and then washed
with ice-cold PBS then lysed for 10 minutes at 4C with agitation in Triton X-100 extraction buffer supplemented with a Roche cOm-
plete, Mini, EDTA-free protease inhibitor cocktail (Millipore Sigma; 11836170001). For 3-Deazaneplanocin A (DZNep), MSTC-2770
were treated for 10 days (1 mM, 2 mM). Lysate was centrifuged at 4C for 10 minutes at 6,500rpm. Supernatant was discarded
and the pellet was washed with TEB and centrifuged as above. Supernatant was discarded and the pellet was resuspended in
0.2N HCl and histones were extracted overnight at 4C. Samples were again centrifuged and supernatant was neutralized with
2MNaOH at a 1:10 volume. Protein was quantified using Bradford assay and protein expression was examined by western blot using
anti-H3K27me3 (Abcam; ab6002) and anti-H3 (CST; 4499S).
Stable cell line generation
For lenti packaging, 5 mg of NRAS sgRNA CRISPR/Cas9 All-in-one vector (ABM: 321511110595) or 5 mg of Scrambled sgRNA
CRISPR/Cas9 All-in-one vector (ABM: K010) was transfected together with packaging plasmids (5 mg) in HEK293T cells using Lip-
ofectamine 3000 according to manufacturer’s instructions. For transduction, lentivirus with DMEM media + 10 mg of polybrene was
reversed transduced with MSTC-2125 cells and transgene selection was performed using 3 mg/mL of puromycin.
Quantitative PCR
qRT-PCR assays were performed after 14 days of GSK-126 (1 mM, 2 mM, 3 mM) or DMSO treatment of melanoma cell lines. Total RNA
was isolated using RNeasy Mini Kit (QIAGEN) and 500ng of RNA from each sample was reverse transcribed using SuperScript VILO
cDNA Synthesis Kit (Thermo Fisher). qRT-PCR was performed with 2 mL of undiluted cDNA in triplicate for each primer set. GAPDH
was used as a housekeeping gene and data was plotted and quantified using https://peerj.com/articles/4473.
Immunohistochemistry for patient tissue microarrays
Immunohistochemical stains were performed on 6 stage III and IVmelanoma tissuemicroarrays (TMA) (Ekmekcioglu et al., 2016; Iida
et al., 2017). After heat mediated epitope retrieval at pH 8.0 for 20 min, the sections were incubated with mouse monoclonal SUZ12,
Clone 3D10 (1:500, ThermoFisher) and mouse monoclonal EZH2, Clone AC22 (1:200, Cell signaling Technology). IHC staining was
performed using a Leica Bond Max automated stainer (Leica Biosystems, Buffalo Grove, IL). The IHC reaction was performed using
Leica Bond Polymer Refine detection kit (Leica Biosystems). Immunoreactive cells were visualized using diaminobenzidine (DAB) as
chromogen followed by counterstaining with hematoxylin. All IHC slides were scanned using an Aperio AT Turbo (Leica Biosystems).
The scoring was performed by a pathologist (RL) using direct microscope evaluation. EZH2 and SUZ12 expression was considered
positive when nuclear staining was present on tumor cells and it was evaluated by H-score, which assesses the percentage of pos-
itive cells (0 to 100) multiplied by the intensity of staining (0 to 3+), with a total score ranging from 0 to 300. H-scores for EZH2 or
SUZ12 in patients harboring an NRAS or BRAF mutation were compared using a t test.
Immunohistochemistry for murine tumor samples
Tumors were fixed in formalin for 24 hours, paraffin embedded, sectioned and stained according to standard procedures. Briefly,
slides were baked at 60C for 1 hour then deparaffinized and rehydrated. After antigen retrieval in citrate buffer, endogenous perox-
idases were inactivated by 3% hydrogen peroxide. Non-specific signals were blocked using Rodent Block M (Biocare RBM961).




Then slides were stained using VIM antibody (Cell Signaling; 5741) overnight at 4C. After overnight incubation, the slides were
washed and incubated with secondary antibody (HRP-polymers, Biocare RMR622) for 30 min at room temperature. The slides
were washed and stained with DAB substrate (ThermoFisher Scientific). The slides were then counterstained with hematoxylin
and mounted with mounting medium (Richard-Allan Scientific). Cells were counted using imageJ based on a minimum of 9 20x im-
ages from each sample. P values were calculated using a wilcoxon test.
In vivo assays
NRAS- and BRAF- mutant melanoma short term cultures (MSTC) were transplanted in the flanks of NUDE mice and observed for
tumor induction. Once visible tumors were formed, the mice were randomly distributed in 4 groups and injected with Vehicle,
GSK-126 (150mg/kg), MEK inhibitor (1mg/kg), or a combination of the two drugs intraperitoneally every other day in 5 mice per
arm. For BRAF inhibitors, mice were injected with Vehicle or BRAF-inhibitor (50mg/kg) every other day in 4 mice per arm. Tumors
were measured every third day and the volume was calculated using 0.5 X L X W X H formula. P values were calculated by a paired
t test for each time point using graph pad prism.
QUANTIFICATION AND STATISTICAL ANALYSIS
For chromatin state analysis and all RNA-seq comparisons significant differences between groups was calculated using a Wilcoxon
test. For western blotting analysis (Figures 5D and 5E), relative density was quantified using ImageJ software, and the values of the
target proteins were normalized to b-Actin. Error bars represent mean ± SEM. For all in-vivo data, tumors were measured every third
day and the volume was calculated using 0.5 3 L 3 W 3 H formula. p values were calculated by a paired t test for each time point
using graph pad prism. For immunohistochemistry of patient tissuemicroarrays, scoring was performed by a pathologist using direct
microscope evaluation. EZH2 and SUZ12 expression was considered positive when nuclear staining was present on tumor cells and
it was evaluated by H-score. H-scores for EZH2 or SUZ12 in patients harboring an NRAS or BRAFmutation were compared using a t
test. For immunohistochemistry of murine tumor samples, cells were counted using imageJ based on a minimum of 9 20x images
from each treatment condition. p values were calculated using a wilcoxon test.
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